, ▁via ▁a ▁de mer ger ▁and ▁subsequent ▁listing ▁of ▁the ▁joint ▁vent ure . ▁This ▁will ▁create ▁two ▁public ly ▁trad ed ▁companies , ▁one ▁foc using ▁on ▁ph arma ce ut ical s ▁and ▁research ▁& ▁development , ▁the ▁other ▁on ▁consumer ▁health care . ▁ ▁Vent ure ▁arms ▁SR ▁One ▁was ▁established ▁in ▁ 1 9 8 5 , ▁by ▁Smith K line ▁Be ech am ▁to ▁invest ▁in ▁new ▁bi ote chn ology ▁companies ▁and ▁continued ▁operating ▁after ▁G SK ▁was ▁formed ; ▁by ▁ 2 0 0 3 , ▁G SK ▁had ▁formed ▁another ▁subs idi ary , ▁G SK ▁Vent ures , ▁to ▁out - lic ense ▁or ▁start ▁new ▁companies ▁around ▁drug ▁candidates ▁that ▁it ▁did ▁not ▁intend ▁to ▁develop ▁further . ▁, ▁SR ▁One ▁t ended ▁to ▁invest ▁only ▁if ▁the ▁company ▁aligned ▁with ▁G SK ' s ▁business . ▁ ▁In ▁September ▁ 2 0 1 9 , ▁G SK ▁announced ▁it ▁would ▁ac quire ▁Sit ari ▁Ph arma ce ut ical s ▁and ▁its ▁trans gl ut amin ase ▁ 2 ▁small ▁mole c ule ▁program ▁for ▁the ▁treatment ▁of ▁cel iac ▁disease . ▁ ▁Research ▁areas ▁and ▁products ▁ ▁Ph arma ce ut ical s ▁G SK ▁manufact ures ▁products ▁for ▁major ▁disease ▁areas ▁such ▁as ▁ast h ma , ▁cancer , ▁in fe ctions , ▁di ab etes ▁and ▁mental ▁health . ▁Medic ines ▁histor ically ▁discovered ▁or ▁developed ▁at ▁G SK ▁and ▁its ▁legacy ▁companies ▁and ▁now ▁sold ▁as ▁gener